NEXTBio Capital Management LP purchased a new position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 183,704 shares of the biopharmaceutical company’s stock, valued at approximately $8,234,000. Xenon Pharmaceuticals comprises about 4.8% of NEXTBio Capital Management LP’s investment portfolio, making the stock its 8th biggest position.
Other institutional investors have also recently made changes to their positions in the company. Danske Bank A S acquired a new position in shares of Xenon Pharmaceuticals during the 3rd quarter worth approximately $32,000. Blue Trust Inc. increased its position in shares of Xenon Pharmaceuticals by 2,560.7% during the 4th quarter. Blue Trust Inc. now owns 745 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 717 shares during the last quarter. Kestra Advisory Services LLC acquired a new position in shares of Xenon Pharmaceuticals during the 4th quarter worth approximately $33,000. Aster Capital Management DIFC Ltd acquired a new position in shares of Xenon Pharmaceuticals during the 3rd quarter worth approximately $39,000. Finally, Osaic Holdings Inc. increased its position in shares of Xenon Pharmaceuticals by 541.4% during the 2nd quarter. Osaic Holdings Inc. now owns 1,225 shares of the biopharmaceutical company’s stock worth $40,000 after purchasing an additional 1,034 shares during the last quarter. Institutional investors and hedge funds own 95.45% of the company’s stock.
Insider Buying and Selling
In other news, Director Gary Patou sold 1,322 shares of Xenon Pharmaceuticals stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $53.14, for a total value of $70,251.08. Following the completion of the sale, the director directly owned 24,896 shares in the company, valued at approximately $1,322,973.44. The trade was a 5.04% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Gillian Cannon sold 1,190 shares of Xenon Pharmaceuticals stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $53.14, for a total transaction of $63,236.60. Following the completion of the sale, the director owned 1,455 shares of the company’s stock, valued at approximately $77,318.70. The trade was a 44.99% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 4.07% of the stock is currently owned by insiders.
Wall Street Analysts Forecast Growth
View Our Latest Research Report on XENE
Xenon Pharmaceuticals Trading Down 0.2%
NASDAQ XENE opened at $52.10 on Friday. Xenon Pharmaceuticals Inc. has a 1-year low of $30.00 and a 1-year high of $63.95. The company has a 50 day moving average of $55.41 and a 200-day moving average of $48.95. The company has a market cap of $5.04 billion, a price-to-earnings ratio of -11.09 and a beta of 0.62.
Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.17) earnings per share for the quarter, meeting analysts’ consensus estimates of ($1.17). During the same quarter last year, the company earned ($0.83) earnings per share. On average, equities research analysts forecast that Xenon Pharmaceuticals Inc. will post -4.92 earnings per share for the current year.
About Xenon Pharmaceuticals
Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.
The company’s pipeline comprises multiple preclinical and clinical programs.
Featured Articles
- Five stocks we like better than Xenon Pharmaceuticals
- Time to Sell? 3 Winners With Fading Technical Momentum
- Why These 2 Hotel Stocks Are Beating Travel Peers
- This Energy Stock Has Quietly Soared 130% in a Year
- 3 ‘Boring’ Dividend Stocks With Tasty Technical Setups
Want to see what other hedge funds are holding XENE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Free Report).
Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
